id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-353844-yaueoq62	Bachanova, Veronika	Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic	2020-04-14		.txt	text/plain	6354	273	35	Two anti-CD19 CAR T-cell products are currently approved by the United States Food and Drug Administration (FDA) and other international regulatory agencies: axicabtagene ciloleucel (axi-cel; Yescarta Ò ; Kite/Gilead) for the treatment of adult relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) [2] , and tisagenlecleucel (tisacel; Kymriah Ò ; Novartis Pharmaceuticals), both for adult R/R DLBCL [3] and pediatric R/R ALL [4] . Patients undergoing CAR T cell therapy are receiving potentially life-saving treatment; therefore, it is paramount to ensure the availability of tocilizumab to mitigate serious toxicity and the need for advanced supportive care measures. Although many clinical trials of unproven benefit are on hold during the COVID-19 pandemic, we believe that rational studies of CRS prevention and treatment should continue because they may provide significant advantages to patients by improving safety, limiting the need for scarce intensive care support, and preserving a possibly limited supply of tocilizumab.	./cache/cord-353844-yaueoq62.txt	./txt/cord-353844-yaueoq62.txt